Text Size

Phase I Study of HAL Formulations Applied to the Cervix in Healthy Volunteers

This study has been terminated.
Sponsor:
Information provided by:
PhotoCure
ClinicalTrials.gov Identifier:
NCT00496171
First received: July 3, 2007
Last updated: January 15, 2009
Last verified: January 2009
History of Changes
  Purpose

The purpose of the study is to determine the most effective formulation of HAL for release of hexaminolevulinate to the cervical epithelium at different doses.


Condition
Healthy

Study Type: Observational
Study Design: Time Perspective: Prospective
Official Title: A Phase I Hexaminolevulinate (HAL) Dose-Finding Study Applying Different Formulations to the Cervix in Healthy Volunteers

Further study details as provided by PhotoCure:

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Female
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • Healthy, pre-menopausal female volunteers

Exclusion Criteria:

  • Acute or chronic disease which could influence the study results
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00496171

Locations
Norway
Riks-Radium University Hospital
Oslo, Norway
Sponsors and Collaborators
PhotoCure
Investigators
Principal Investigator: Claes G Tropé, MD PhD Riks-Radium University Hospital
  More Information

No publications provided

ClinicalTrials.gov Identifier: NCT00496171     History of Changes
Other Study ID Numbers: PC CE102/07
Study First Received: July 3, 2007
Last Updated: January 15, 2009
Health Authority: Norway: Norwegian Medicines Agency
Norway:National Committee for Medical and Health Research Ethics

ClinicalTrials.gov processed this record on May 19, 2013